HIV Drugs
Jun 24, 2025
Incyte’s MONJUVI Combo Approved by FDA for Relapsed/Refractory Follicular Lymphoma; Gilead’s YEZTUGO Becomes First FDA-Approved HIV Prevention with 6-Month Protection; FDA Reviewing Incyte’s OPZELURA for Pediatric Atopic Dermatitis (Ages 2–11); Archeus Technologies Receives FDA Clearance for Prostate Cancer Therapy ART-101; Cycle Pharmaceuticals’ HARLIKU Gets First FDA Approval for Alkaptonuria
Incyte’s MONJUVI Combo Approved by FDA for Relapsed/Refractory Follicular Lymphoma Incyte has announced that the FDA has approved MONJUVI (tafasitamab-cxix) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). This makes it the f...
Read More...
Nov 19, 2021
Top Drugs To Watch in HIV (2025)
Human Immunodeficiency Virus or HIV is a species of Lentivirus (genus of retrovirus) that attacks the body’s immune system and obstructs the body’s ability to fight outer infections. The virus can be transmitted when contacted with infected blood, semen or vaginal fluids. HIV attacks the immune cells of the body ma...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
